Evelo Biosciences Reports Top-Line Results From Its Phase 2 Clinical Study With EDP2939 In Moderate Psoriasis; Primary Endpoint Was Not Achieved
Portfolio Pulse from Benzinga Newsdesk
Evelo Biosciences has reported top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis. The primary endpoint was not achieved.
October 17, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evelo Biosciences' Phase 2 clinical trial for EDP2939 in moderate psoriasis did not meet its primary endpoint. This could negatively impact the company's stock price in the short term.
Clinical trial results are a significant factor in a biotech company's valuation. Failure to meet the primary endpoint in a Phase 2 trial indicates that the drug may not be as effective as hoped, which could negatively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100